Y-90 radioembolization plus treatment for high-risk liver cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed hepatocellular carcinoma (liver cancer), staged as Child-Pugh A or B7.
- You have at least one tumor spot that can be measured on scans (including a previously treated spot that has clearly grown).
- You can have had prior cancer treatments (including none), but you cannot have had prior PD-1/PD-L1 treatment for any cancer.
- You are age 18 or older, with a performance status (energy/function) score of 0–2.
- Your blood counts and organ tests must be strong enough for treatment (including certain hemoglobin, kidney, liver, and clotting levels).
- If you can become pregnant (or are a sexually active male with a partner who can), you must use two forms of birth control and have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors through a tube. It is for people with one or a few small liver tumors that cannot be removed with surgery or destroyed with heat or cold. The goal is to shrink or control the tumors with fewer side effects.
This study looks at how well Y90 “radioembolization” treatment delivers radiation and how much radiation reaches your body. If you can safely get extra PET/CT scans and blood tests around your treatment, you may be invited to participate.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a treatment called yttrium-90 radioembolization (tiny radioactive beads delivered to the liver) for people with liver cancer that has already been treated before. The goal is to see if it can help control the tumor when other treatments haven't been enough.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.